3-HO-PCE

Coronary artery disease, Heart failure, Uncontrolled hypertension

Class-level toxidrome data from 25 O-PCE cases showed hypertension in 80% and tachycardia in 40% of presentations. Individuals with pre-existing cardiovascular disease, uncontrolled hypertension, or heart failure face elevated risk.

COPD, Obstructive sleep apnea, Restrictive lung disease

The 3-hydroxy substitution confers mu-opioid receptor agonism (demonstrated for 3-HO-PCP by Itzhak et al. 1981), which suppresses respiratory drive. Individuals with obstructive sleep apnea, COPD, or other respiratory conditions face elevated risk of fatal respiratory failure.

Epilepsy, History of seizures, Medications lowering seizure threshold

Convulsions occurred in 16% of analytically confirmed O-PCE (eticyclidine family) acute poisoning cases (Tang et al. 2018). Individuals with epilepsy or lowered seizure threshold face elevated risk.

Schizophrenia, Schizoaffective disorder, Psychotic disorder NOS, Bipolar I with psychotic features

NMDA antagonists produce a schizophrenia-like psychosis in humans (Farber et al. 1996) and may precipitate persistent psychotic episodes in vulnerable individuals. This is a well-established class-level risk for all arylcyclohexylamines.

Cirrhosis, Severe hepatic impairment, Concurrent CYP2B6 inhibitor use

Metabolism is inferred to proceed primarily via CYP2B6 and CYP3A4 (by ketamine analogy). Hepatic impairment would reduce clearance of parent compound and metabolites, prolonging exposure. CYP2B6 inhibition produced a 2.4-fold increase in oral S-ketamine AUC.

Chronic kidney disease, Acute kidney injury

Phase II metabolism produces O-glucuronide conjugates (Larabi et al. 2023) requiring renal elimination. Impaired renal function would prolong exposure. Additionally, rhabdomyolysis has been documented with arylcyclohexylamine derivatives, compounding renal risk.

Pregnancy, Planned pregnancy

NMDA receptors play critical roles in neurodevelopment. Antagonism during fetal development disrupts neuronal migration, synaptogenesis, and programmed cell death. No reproductive toxicity data exists for 3-HO-PCE. The additional opioid component raises concern for neonatal opioid withdrawal.

Concurrent fentanyl use, Concurrent heroin use, Concurrent methadone use, Concurrent codeine use

Co-administration with exogenous opioids (fentanyl, heroin, methadone, codeine, tramadol) creates additive mu-opioid receptor activation. All published fatalities involving 3-HO-PCP and 3-MeO-PCE occurred in polydrug contexts, with methadone co-ingestion documented in the Ameline et al. 2023 fatality.

Concurrent benzodiazepine use, Concurrent alcohol use, Concurrent GHB/GBL use, Concurrent barbiturate use

Combination with CNS depressants produces additive respiratory and CNS depression. Every published fatality involving 3-HO-PCP or 3-MeO-PCE occurred in polydrug contexts with CNS depressants. The opioid component of 3-HO-PCE makes this interaction qualitatively more dangerous than equivalent combinations with ketamine.